Immunotherapy-Small Molecule Combination Functional Drug Response -
CytoImage Dx has developed a proprietary platform technology that provides multiplexed quantification of protein function in single cells with exceptionally sensitive evaluation of the drug response. CytoImage performs validated blood-based assays for functional drug sensitivity screening in ex vivo (pre-clinical) and in vitro (clinical) patient testing environments.
The future of cancer treatment will leverage the potential of combination therapy, driven by the advancements in Immuno-Oncology. The challenge is to find the right combinations of immunotherapy drug combinations and match them to the right patients.
CytoImage Dx is presenting as part of the NIH Innovation Zone.